TeamDrive
RUS
Vladimir Gurdus

Vladimir Gurdus

Founding Partner, COO

Телефоны:

+7 495 545-39-12

Send message

Vladimir is the CEO of RMI Partners, which manages the projects of RusnanoMedInvest LLC and NovaMedica LLC.  He is also the co-founder and member of the Board of Directors of RMI Partners (venture capital investment company), Team Drive (management of major projects) and Doctor Ryadom (network of medical clinics).

Since 2012 Vladimir has been part of the leadership team at the company, implementing a major pharmaceutical and medical project, the brainchild of its investors RUSNANO OJSC and the American firm Domain Associates LLC. RusnanoMedInvest LLC (RMI) was founded to implement this project. RMI is the largest venture capital company in life sciences in Eastern Europe, focusing on innovative pharmaceutical projects backed by sustainable, cutting edge technologies. Initial project funding is US$380 million. Russian pharmaceutical company NovaMedica LLC is responsible for the localisation of the products and technologies in Russia. It was also founded to implement ambitious plans to create a new GMP-compliant production facility and facilitate the production of innovative drugs.

Before assuming a key role as one of the project’s leaders, from 2007 to 2009 Vladimir was President at Medsi Group (part of AFK Sistema) and played a key role in transforming it into the leading privately-held medical service provider. Previously he had played an active role in starting up the ROSNO insurance company. After becoming a leading player on the Russian insurance market, ROSNO was acquired by the world’s largest insurance company Allianz Holding.  From 1991 to 2007 he was First Deputy CEO of ROSNO, and also the COO and CEO of ROSNO Group subsidiaries, such as ROSNO-MS. In 2006, after the acquisition of ROSNO by Allianz, Vladimir was appointed CEO of Allianz ROSNO-Life.

He is also an investor and the founder of a number of successful start-ups in the medical, insurance and IT sectors.

Vladimir is a member of the Government Expert Council of the Russian Federation. This organisation was established to involve the business community in the preparation and implementation of the decisions of the Russian Government, and also to ensure public oversight over the work of the federal authorities. Members of the Council attend the meetings of the Russian government, government and interdepartmental commissions and committees, and perform expert reviews of the draft decisions of the Russian government and federal executive agencies and the results of implementation. As a member of the Expert Council Vladimir proactively tackles issues of developing the Russian healthcare and pharmaceutical sectors. He also co-chairs a joint working group of the Expert Council and the Ministry of Health, whose chief remit is to draft the development framework of a healthcare system and the provision of the medicines required by the Russian population drug.

Vladimir is a member of the Public Council under the Ministry of Health of the Russian Federation – a permanent consultative public health oversight body.

Vladimir graduated cum laude from I.M. Sechenov Moscow Medical Academy. He has a second degree in finance and economics at RosNOU. Vladimir is a Doctor of Medical Sciences and Professor. 

Media Center

  • 26 September 2017

    Iranian biotech drugs replaced American ones in Russia

    Iranian biotech medicines exported to Russia have taken over the country’s market 100% and have replaced their American versions, according to National Talents Foundation.

  • 26 September 2017

    Pfizer and LabCentral announced opening of a new facility

    LabCentral and Pfizer announced plans to open LabCentral 610, a new LabCentral offering located at Pfizer’s Kendall Square Worldwide Research and Development campus, Cambridge, Massachusetts, U.S. The facility is slated to open in December and will house up to six early- to mid-stage companies.

  • 25 September 2017

    Russian University creates a bank of biomolecules for new drugs

    The research activities of Genomic and Regenerative Medicine Center established at the School of Biomedicine in the Far Eastern Federal University (FEFU) will be based on unique natural resources of the Russian Far East. The scientists will study the biodiversity of the region, including marine organisms, create a bank of biomolecules for new drugs, and introduce innovative diagnostic and treatment methods into routine medical practice.

  • 25 September 2017

    Transition to multicomponent preventive drugs is necessary

    During the second BIOTECHMED conference held in Gelendzhik, the representatives of Nacimbio, a company which is part of Rostec Corporation, participated in panel discussions on preventive vaccination and expansion of the National Immunization Calendar.

Read more